NCT03082833终止2 期
Samsung Medical Center
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR) by RECIST 1.1
研究概览
简要总结
Phase II trial of AZD2014 in TSC1/2 mutated or TSC1/2 null GC patients as second-line chemotherapy
详细描述
AZD2014 50mg BD continuous schedule of a 28 day cycle AZD2014 will be administered with orange juice in STG/TG patients. AZD2014 can be taken with or without food. The first dose of the day should be taken at approximately the same time each morning.The second dose of the day should be taken approximately 12 hours after the morning dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of fully informed consent prior to any study specific procedures.
- •Patients must be ≥20 years of age.
- •Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after first-line therapy.
- •The 1st line regimen must have contained doublet 5-fluoropyrimidine and platinum based regimen.
- •Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy containing doublet 5-fluoropyrimidine and platinum-based regimen could be considered as 1st line therapy.
- •Acceptable prior chemotherapy regimens for this protocol are chemotherapy regimens that include Immune Target agent therapy. (such as a pembrolizumab, ramucirumab etc)
- •Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months prior to starting the 1st line therapy.
- •Provision of tumor sample (from eith tumor sample (from eith tumor sample (from eith tumor sample (from eith tumor sample (from eith er a resection or biopsy)er a resection or biopsy) er a resection or biopsy)er a resection or biopsy) er a resection or biopsy)er a resection or biopsy)er a resection or biopsy)er a resection or biopsy)er a resection or biopsy) er a resection or biopsy) er a resection or biopsy) er a resection or biopsy)er a resection or biopsy)
- •Patients with TSC1/2 mutation or null through the VIKTORY trial. (The VIKTORY trial uses Ion Torrent PGM to screen for a panel of cancer mutations and nanostring copy number variation panel (see addendum for the VIKTORY trial). Types of TSC1/2 mutation for this trial was defined in VIKTORY lab manual
- •Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •ECOG performance status 0-
- •Patients must have a life expectancy ≥ 3 months from proposed first dose date.
- •Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below:
- •Haemoglobin ≥9.0 g/dL (transfusion allowed)
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- •White blood cells (WBC) > 3 x 109/L
- •Platelet count ≥100 x 109/L (transfusion allowed)
- •Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
- •AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN
- •Serum creatinine ≤1.5 x institutional ULN
- •At least one measurable lesion that can be accurately assessed by imaging or physical examination at baseline and following up visits.
- •Negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day
- •Patients of child-bearing potential should be using adequate contraceptive measures (two forms of highly reliable methods) should not be breast feeding and must have a negative pregnancy test prior to start of dosing.Or Patients must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: Post-menopausal - defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation
排除标准
- •More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy with more than 6 month wash out period) for the treatment of gastric cancer in the advanced setting.
- •Any previous treatment with PIK3CA, AKT or mTOR inhibitor or agents with mixed PI3K / mTOR activity.
- •Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤5 years.
- •Patients unable to swallow orally administered medication.
- •Previous major surgery within 4 weeks prior to enrollment.
- •For AZD2014: Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout periods before the first dose of study treatment
- •With the exception of alopecia, any ongoing toxicities (>CTCAE grade 1) caused by previous cancer therapy.
- •Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the enrollment.
- •Resting ECG with measurable QTcB > 450 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
- •Patients with cardiac problem as follows: uncontrolled hypertension (BP ≥150/95 mmHg despite medical therapy) Left ventricular ejection fraction <55% measured by echocardiography, Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy, Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to starting treatment
- •Active or untreated brain metastases or spinal cord compression Patients with treated brain metastases or spinal cord compression are eligible if they have minimal neurologic symptoms, evidence of stable disease (for at least 1 month) or response on follow-up scan, and require no corticosteroid therapy for ≥ 1 week.
- •Female patients who are breast-feeding or child-bearing
- •Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
- •Patients with proteinuria (3+ on dipstick analysis )
研究组 & 干预措施
AZD2014 50mg BD
Experimental
AZD2014 50mg BD continuous schedule of a 28 day cycle
干预措施: AZD2014 (Drug)
结局指标
主要结局
Objective response rate (ORR) by RECIST 1.1
时间窗: 6 months
Objective response rate (ORR) by RECIST 1.1
次要结局
未报告次要终点
研究者
Jeeyun Lee
professor
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
终止
2 期
Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line TherapyStomach NeoplasmsNCT03061708Samsung Medical Center1
进行中（未招募）
1 期
A study of AZD1775 plus Chemotherapy in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerEUCTR2015-000886-30-GBAstraZeneca AB97
已完成
2 期
A Multicentre Phase II Study of AZD1775 plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.NL-OMON46453Astra Zeneca6
进行中（未招募）
1 期
A study of AZD1775 plus Chemotherapy in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.EUCTR2015-000886-30-NLAstraZeneca AB97
进行中（未招募）
2 期
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2AAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAdult ErythroleukemiaAdult Pure Erythroid LeukemiaSecondary Acute Myeloid LeukemiaNCT00658814National Cancer Institute (NCI)133